Imprecision remains to be improved in the measurement of serum cystatin C with heterogeneous systems
Author:
Zeng Jie1, Zhang Li2, Zhang Jiangtao1, Zhou Weiyan1ORCID, Zhang Tianjiao1, Wang Jing1, Zhao Haijian1, Zhang Chuanbao1ORCID
Affiliation:
1. National Center for Clinical Laboratories, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing Engineering Research Center of Laboratory Medicine , Institute of Geriatric Medicine , Beijing , P.R. China 2. National Center for Clinical Laboratories, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing Engineering Research Center of Laboratory Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College , Institute of Geriatric Medicine , Beijing , P.R. China
Abstract
Abstract
Objectives
Except for the large bias of some measurement systems for serum cystatin C (CysC) measurements, unacceptable imprecision has been observed for the heterogenous system. This study analyzed the external quality assessment (EQA) results in 2018–2021 to provide an insight into the imprecision of CysC assays.
Methods
Five EQA samples were sent to participating laboratories every year. Participants were divided into reagent/calibrator-based peer groups, for which the robust mean of each sample and robust coefficient of variation (CV) were calculated by Algorithm A from ISO 13528. Peers with more than 12 participants per year were selected for further analysis. The limit of CV was determined to be 4.85% based on clinical application requirements. The concentration-related effect on CVs was investigated using logarithmic curve fitting; the difference in medians and robust CVs between instrument-based subgroups was also evaluated.
Results
The total number of participating laboratories increased from 845 to 1,695 in four years and heterogeneous systems remained the mainstream (≥85%). Of 18 peers with ≥12 participants, those using homogeneous systems showed relatively steady and small CVs over four years, with the mean four-year CVs ranging from 3.21 to 3.68%. Some peers using heterogenous systems showed reduced CVs over four years, while 7/15 still had unacceptable CVs in 2021 (5.01–8.34%). Six peers showed larger CVs at the low or high concentrations, and some instrument-based subgroups presented greater imprecision than others.
Conclusions
More efforts should be made to improve the imprecision of heterogeneous systems for CysC measurement.
Funder
National Key Research and Development Program of China
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference25 articles.
1. Eckardt, KU, Coresh, J, Devuyst, O, Johnson, RJ, Köttgen, A, Levey, AS, et al.. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158–69. https://doi.org/10.1016/s0140-6736(13)60439-0. 2. Vijay, P, Lal, BB, Sood, V, Khanna, R, Alam, S. cystatin C: best biomarker for acute kidney injury and estimation of glomerular filtration rate in childhood cirrhosis. Eur J Pediatr 2021;180:3287–95. https://doi.org/10.1007/s00431-021-04076-1. 3. Lees, JS, Welsh, CE, Celis-Morales, CA, Mackay, D, Lewsey, J, Gray, SR, et al.. Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nat Med 2019;25:1753–60. https://doi.org/10.1038/s41591-019-0627-8. 4. Casal, MA, Nolin, TD, Beumer, JH. Estimation of kidney function in oncology: implications for anticancer drug selection and dosing. Clin J Am Soc Nephrol 2019;14:587–95. https://doi.org/10.2215/cjn.11721018. 5. Lameire, NH, Levin, A, Kellum, JA, Cheung, M, Jadoul, M, Winkelmayer, WC, et al.. Harmonizing acute and chronic kidney disease definition and classification: report of a kidney disease: improving global Outcomes (KDIGO) consensus conference. Kidney Int 2021;100:516–26. https://doi.org/10.1016/j.kint.2021.06.028.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|